Spinal Intervention: Markets for Surgical, Replacement and Neurostimulation Technologies
- January 2017
- 181 pages
- Report ID: 4579511
Use this report to:
- Measure a broad understanding of the market for spinal interventional products, as well as the markets for adjacent but complementary products and technologies.
- Analyze the market in terms of key product and technology areas, major manufacturers and factors influencing market growth.
- Provide a more comprehensive analysis of the overall market and growth opportunities for companies operating in the spinal interventional market.
- Discuss major stakeholders, product portfolios and recent developments, and to draw a competitive landscape for the market leaders in the spinal interventional market.
- The global market for spinal and neurostimulation intervention products is expected to reach $15.8 billion by 2021 from $12.6 billion in 2016, rising at a compound annual growth rate (CAGR) of 4.5% from 2016 through 2021.
- The spinal surgery segment of spinal intervention market is the largest sector. The market is expected to grow from $9.0 billion in 2016 to $10.8 billion in 2021 at a CAGR of 3.5% for the period 2016-2021.
- The neurostimulation devices segment of spinal intervention market is expected to grow from $3.6 billion in 2016 to $5.0 billion in 2021 at a CAGR of 6.9% for the period 2016-2021.
STUDY GOALS AND OBJECTIVES
This report, Spinal Intervention: Markets for Surgical, Replacement and Neurostimulation Technologies, provides an in-depth analysis of the markets for spinal and neurostimulation products. It aims to provide readers with a broad understanding of the market for spinal interventional products, as well as the markets for adjacent but complementary products and technologies.
REASONS FOR DOING THE STUDY
In the U.S. alone, back pain has an estimated direct cost of over $50 billion annually for diagnosis, treatment and rehabilitation. Currently, it is estimated that there are approximately 65 million people in the U.S. alone with chronic back pain. The treatment of back pain depends much on the root cause. Generally, pharmaceuticals and/or physical therapy are the first-line treatments. However, should these not work, spinal surgery may be an option for some patients. Currently, over 1 million spinal surgeries are performed each year. Given the aging population, these rates are expected to continue to increase in coming years, leading to a good market opportunity for companies working in this space.
As an alternative to spinal surgery, neurostimulation has become a new option for the treatment of lower back pain in recent years. In addition to treating pain, neurostimulation can be used to treat unwanted neurological or psychological symptoms, as well as to enhance muscular activity. As such, neurostimulation can be used, or is being investigated for use, to treat a wide range of conditions, including chronic migraine, cluster headache, Parkinson’s disease, essential tremor, dystonia, epilepsy, overactive bladder, fecal incontinence, gastroparesis, obesity, gastroesophageal reflux disease, sleep apnea, treatment-resistant hypertension, obsessive-compulsive disorder, depression, heart failure, Alzheimer’s disease, tinnitus and upper-limb deficit after stroke. This is a dynamic and growing market that is attracting increasing interest from manufacturers, surgeons and patients alike.
SCOPE OF REPORT
The report provides an analysis of the markets for spinal and neurostimulation products, including trends and sales to 2021. It analyzes the market in terms of key product and technology areas, major manufacturers and factors influencing market growth.
Manufacturers of neurostimulation and spinal technologies are discussed and analyzed based on product types, market share and key corporate activities, including a mergers and acquisitions, strategic alliances, and research and development. In addition to neurostimulation products used for the treatment of spinal conditions, the report looks at the wider neurostimulation industry in order to provide a more comprehensive analysis of the overall market and growth opportunities for companies operating in this field.
The report also includes an in-depth analysis of new products and technologies in development, as well as the development of new products that can address a growing number of therapeutic indications. Excluded from the scope of the report are spinal soft goods, bracing products and externally worn neurostimulation devices.
INTENDED AUDIENCE The report is intended for anyone interested in gaining a better understanding of the spinal implant and neurostimulation markets. This may include company executives working in these areas, those planning or contemplating investing in the market, companies actively or considering pursuing market entry, component or materials manufacturers whose products may be relevant to the industry, suppliers and distributors working in this field. In addition, the report would be of interest to venture capitalists, clinicians, trade associations, research organizations and government bodies with an interest in spinal and neurostimulation products and technologies.
The information contained in the report comes from a wide range of primary and secondary sources. Financial and market data are derived from U.S. Securities and Exchange Commission filings, company annual reports and other financial reports, company investor presentations, trade associations, industry associations and company executives. Product and technology sources include company press releases and websites, information from professional organization and industry conferences, medical research papers and medical journal articles, U.S. Patent Office filings and U.S. Food and Drug Administration databases and resources, as well as similar sources available for countries other than the U.S.
Other major sources of information include government bodies such as the U.S. Center of Disease Control and Prevention, the U.S. Department of Health and Human Services and the World Health Organization, as well as similar bodies in other countries. In addition, the report has been complied with the help of direct communication with company executives, including CEOs, product managers, marketing managers, investor relations and research and development staff.
ANALYST'S CREDENTIALS Joanne Maddox is an experienced healthcare industry analyst specializing on the medical device and diagnostics markets. She has 16 years of experience working specifically in this niche area. Her work has included competitor and market insight, due diligence assistance, market forecasting and trend analysis of the medical devices industry, with a key focus on orthopedic and spinal technologies, implantable electronic devices, diagnostics, medical imaging and wound care.